Poolbeg Pharma

Oncology

How today’s biotechs are helping us Stand Up To Cancer

In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.

News

Jeremy Skillington, Poolbeg's chief executive

Poolbeg expects first data for CRS drug in the summer

A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.

Oncology

Interview at ESMO 2025 with Liam Tremble

ESMO25: Transforming the cancer immunotherapy field, with Po...

Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.

News

Poolbeg slumps as Hookipa merger is called off

A proposed merger of the UK's Poolbeg with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations.

News

London-listed Poolbeg discussing Hookipa merger

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.

News

Poolbeg licences candidate for broad-spectrum respiratory in...

Poolbeg Pharma has licenced a candidate for nasal immunotherapy, developed by the University of Warwick, targeting respiratory infections, such as influenza and coronavirus.

How today’s biotechs are helping us Stand Up To Cancer

Poolbeg expects first data for CRS drug in the summer

ESMO25: Transforming the cancer immunotherapy field, with Po...

Poolbeg slumps as Hookipa merger is called off

London-listed Poolbeg discussing Hookipa merger

Poolbeg licences candidate for broad-spectrum respiratory in...

ESMO26: Taiho Oncology on improving the lives of patients wi...

Discover a new era of healthcare panel engagement: Grounded ...

Poolbeg Pharma

Editor's Picks